Trek Financial LLC Boosts Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Trek Financial LLC increased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 15.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,638 shares of the company’s stock after buying an additional 1,021 shares during the period. Trek Financial LLC’s holdings in Amphastar Pharmaceuticals were worth $284,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Pacer Advisors Inc. raised its position in Amphastar Pharmaceuticals by 51,977.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after acquiring an additional 1,347,775 shares during the period. Boston Trust Walden Corp raised its position in shares of Amphastar Pharmaceuticals by 81.4% during the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock worth $36,347,000 after purchasing an additional 439,281 shares during the last quarter. Boston Partners purchased a new position in Amphastar Pharmaceuticals in the 4th quarter valued at about $15,778,000. Wealthfront Advisers LLC acquired a new stake in Amphastar Pharmaceuticals in the 4th quarter worth about $9,268,000. Finally, Raymond James Financial Inc. purchased a new stake in Amphastar Pharmaceuticals during the 4th quarter worth approximately $3,450,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

AMPH opened at $25.00 on Tuesday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $24.71 and a twelve month high of $53.96. The firm has a market capitalization of $1.19 billion, a PE ratio of 8.33, a PEG ratio of 2.19 and a beta of 0.79. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The firm’s 50-day moving average price is $29.99 and its 200 day moving average price is $39.00.

Analyst Upgrades and Downgrades

Separately, Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research report on Friday, March 21st.

Insider Transactions at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.